RLMD Relmada Therapeutics
- 3.830
- +0.010+0.26%
- 4.250
- +0.420+10.97%
Relmada Therapeutics News
Relmada Therapeutics Q1 2024 GAAP EPS $(0.72) Beats $(0.84) Estimate
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.84) by 14.29 percent. This is a 17.24 percent increase over losses of
Relmada Therapeutics | 10-Q: Quarterly report
Press Release: Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results PR Newswire CORAL GABLES, Fla., May 8, 2024 CORAL GABLES, Fla., May 8, 2024 /PRNewswire/ -- Relmada T
Express News | Relmada Therapeutics Q1 EPS USD -0.72
Express News | Relmada Therapeutics Q1 Net Income USD -21.8 Million
Express News | Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Express News | Relmada Therapeutics Q1 Cash & Investments USD 83.6 Million
Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics)
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Laidlaw's James Ahern Named to Crain's New York Notable Leaders in Finance 2024
NEW YORK, March 26, 2024 /PRNewswire/ -- Laidlaw & Co. Managing Partner James Ahern has been named one of Crain's New York's Notable Leaders in Finance for 2024. Mr. Ahern has been at Laidlaw for fou
Optimistic Outlook for Relmada Therapeutics: A Comprehensive Analysis and Buy Rating
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q4 2023 Earnings Conference
The following is a summary of the Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript:Financial Performance:Business Progress:More details: Relmada Therapeutics IRTips: This article is
Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results
Relmada Therapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.83) by 1.2 percent. This is a 34.38 percent increase over losses of
Recap: Relmada Therapeutics Q4 Earnings
Relmada Therapeutics (NASDAQ:RLMD) reported its Q4 earnings results on Tuesday, March 19, 2024 at 04:15 PM.Here's what investors need to know about the announcement.EarningsRelmada Therapeutics missed
Relmada Therapeutics GAAP EPS of -$0.84
Relmada Therapeutics 2023 EPS $(3.28)
Relmada Therapeutics 2023 EPS $(3.28)
Relmada Therapeutics: Provides Corporate Update and Reports 4Q and Full-Yr 2023 Fincl Results
Relmada Therapeutics: Provides Corporate Update and Reports 4Q and Full-Yr 2023 Fincl Results
Relmada Therapeutics: As of Dec 31, 2023, Had Cash, Cash Equivalents, Short-Term Investments of Approximately $96.3M, Compared to Cash, Cash Equivalents, Short-Term Investments of Approximately $148.3M at Dec 31, 2022 >RLMD
Relmada Therapeutics: As of Dec 31, 2023, Had Cash, Cash Equivalents, Short-Term Investments of Approximately $96.3M, Compared to Cash, Cash Equivalents, Short-Term Investments of Approximately $148.3
Analysis
Price Target
No Data
